JP7721520B2 - 肺動脈性肺高血圧症の治療方法 - Google Patents

肺動脈性肺高血圧症の治療方法

Info

Publication number
JP7721520B2
JP7721520B2 JP2022531531A JP2022531531A JP7721520B2 JP 7721520 B2 JP7721520 B2 JP 7721520B2 JP 2022531531 A JP2022531531 A JP 2022531531A JP 2022531531 A JP2022531531 A JP 2022531531A JP 7721520 B2 JP7721520 B2 JP 7721520B2
Authority
JP
Japan
Prior art keywords
macitentan
therapy
tadalafil
selexipag
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022531531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504115A5 (cg-RX-API-DMAC10.html
JP2023504115A (ja
Inventor
マレスタ アレッサンドロ
ペルシュネット ロイク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73726769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7721520(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of JP2023504115A publication Critical patent/JP2023504115A/ja
Publication of JP2023504115A5 publication Critical patent/JP2023504115A5/ja
Priority to JP2024118344A priority Critical patent/JP7620758B2/ja
Priority to JP2025127467A priority patent/JP2025172745A/ja
Application granted granted Critical
Publication of JP7721520B2 publication Critical patent/JP7721520B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022531531A 2019-11-29 2020-11-27 肺動脈性肺高血圧症の治療方法 Active JP7721520B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024118344A JP7620758B2 (ja) 2019-11-29 2024-07-24 肺動脈性肺高血圧症の治療方法
JP2025127467A JP2025172745A (ja) 2019-11-29 2025-07-30 肺動脈性肺高血圧症の治療方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962941910P 2019-11-29 2019-11-29
US62/941,910 2019-11-29
US202063023452P 2020-05-12 2020-05-12
US63/023,452 2020-05-12
US202063076149P 2020-09-09 2020-09-09
US63/076,149 2020-09-09
PCT/EP2020/083593 WO2021105331A1 (en) 2019-11-29 2020-11-27 Methods of treating pulmonary arterial hypertension

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024118344A Division JP7620758B2 (ja) 2019-11-29 2024-07-24 肺動脈性肺高血圧症の治療方法
JP2025127467A Division JP2025172745A (ja) 2019-11-29 2025-07-30 肺動脈性肺高血圧症の治療方法

Publications (3)

Publication Number Publication Date
JP2023504115A JP2023504115A (ja) 2023-02-01
JP2023504115A5 JP2023504115A5 (cg-RX-API-DMAC10.html) 2023-12-04
JP7721520B2 true JP7721520B2 (ja) 2025-08-12

Family

ID=73726769

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022531531A Active JP7721520B2 (ja) 2019-11-29 2020-11-27 肺動脈性肺高血圧症の治療方法
JP2024118344A Active JP7620758B2 (ja) 2019-11-29 2024-07-24 肺動脈性肺高血圧症の治療方法
JP2025127467A Pending JP2025172745A (ja) 2019-11-29 2025-07-30 肺動脈性肺高血圧症の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024118344A Active JP7620758B2 (ja) 2019-11-29 2024-07-24 肺動脈性肺高血圧症の治療方法
JP2025127467A Pending JP2025172745A (ja) 2019-11-29 2025-07-30 肺動脈性肺高血圧症の治療方法

Country Status (18)

Country Link
US (1) US12485119B2 (cg-RX-API-DMAC10.html)
EP (1) EP4065119B1 (cg-RX-API-DMAC10.html)
JP (3) JP7721520B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220106974A (cg-RX-API-DMAC10.html)
CN (1) CN114728002A (cg-RX-API-DMAC10.html)
AU (1) AU2020392424A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022010311A2 (cg-RX-API-DMAC10.html)
CA (1) CA3158292A1 (cg-RX-API-DMAC10.html)
CR (1) CR20220305A (cg-RX-API-DMAC10.html)
EC (1) ECSP22051163A (cg-RX-API-DMAC10.html)
ES (1) ES2994089T3 (cg-RX-API-DMAC10.html)
IL (1) IL293271A (cg-RX-API-DMAC10.html)
JO (1) JOP20220127A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022006403A (cg-RX-API-DMAC10.html)
PE (1) PE20221320A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022551294A1 (cg-RX-API-DMAC10.html)
TW (1) TW202133851A (cg-RX-API-DMAC10.html)
WO (1) WO2021105331A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024099953A1 (en) * 2022-11-07 2024-05-16 Actelion Pharmaceuticals Ltd Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension
KR102663470B1 (ko) * 2023-03-16 2024-05-10 주식회사 케어사이드 폐성 고혈압에 의한 심장 질환 예방 및 심장 치료용 조성물 및 이를 포함하는 기능성 제제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506752A (ja) 2003-09-24 2007-03-22 コゼリクス、 インク. 肺動脈高血圧症を治療するための併用療法におけるイロプロスト
WO2015163098A1 (ja) 2014-04-22 2015-10-29 国立大学法人東北大学 肺高血圧症の検査方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693372A1 (en) 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Novel Sulfamides and their use as endothelin receptor antagonists
TWI316055B (cg-RX-API-DMAC10.html) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX350011B (es) 2008-08-13 2017-08-22 Actelion Pharmaceuticals Ltd Composiciones terapeuticas que contienen macitentan.
SG176915A1 (en) 2009-06-26 2012-01-30 Nippon Shinyaku Co Ltd Crystals
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
EA026074B1 (ru) 2010-10-15 2017-02-28 Джилид Сайэнс, Инк. Способы, включающие применение композиции амбризентана и тадалафила для лечения легочной артериальной гипертензии
AU2016207046B2 (en) * 2015-01-13 2021-04-01 Vivus Llc Combination therapy for pulmonary hypertension
RU2763525C2 (ru) * 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
EP3897646B1 (en) * 2018-12-21 2024-05-22 Actelion Pharmaceuticals Ltd Macitentan for the treatment of pulmonary arterial hypertension

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506752A (ja) 2003-09-24 2007-03-22 コゼリクス、 インク. 肺動脈高血圧症を治療するための併用療法におけるイロプロスト
WO2015163098A1 (ja) 2014-04-22 2015-10-29 国立大学法人東北大学 肺高血圧症の検査方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eur. Respir. Rev.,2016年,Vol. 25,pp. 408-417

Also Published As

Publication number Publication date
ECSP22051163A (es) 2022-07-29
JOP20220127A1 (ar) 2023-01-30
CR20220305A (es) 2022-07-28
EP4065119B1 (en) 2024-09-04
PH12022551294A1 (en) 2023-11-20
TW202133851A (zh) 2021-09-16
US12485119B2 (en) 2025-12-02
JP7620758B2 (ja) 2025-01-23
JP2024153734A (ja) 2024-10-29
CA3158292A1 (en) 2021-06-03
CN114728002A (zh) 2022-07-08
KR20220106974A (ko) 2022-08-01
IL293271A (en) 2022-07-01
EP4065119A1 (en) 2022-10-05
JP2023504115A (ja) 2023-02-01
BR112022010311A2 (pt) 2022-08-16
US20230032813A1 (en) 2023-02-02
WO2021105331A1 (en) 2021-06-03
AU2020392424A1 (en) 2022-06-02
JP2025172745A (ja) 2025-11-26
ES2994089T3 (en) 2025-01-17
PE20221320A1 (es) 2022-09-08
MX2022006403A (es) 2022-08-25

Similar Documents

Publication Publication Date Title
US20240423981A1 (en) Treatment of hcm with pyrimidinedione compounds
JP7620758B2 (ja) 肺動脈性肺高血圧症の治療方法
US20220323437A1 (en) Methods for treating pulmonary arterial hypertension
WO2010062640A1 (en) Methods for treating idiopathic pulmonary fibrosis and associated complications
JP2022527210A (ja) 門脈肺高血圧症の治療に使用するためのマシテンタン
WO2025106686A1 (en) Methods of treating pediatric low-grade glioma
KR20250150635A (ko) 인자 b 억제제의 사용 방법
WO2024099953A1 (en) Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension
HK40026724B (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
HK40026724A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231010

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250730

R150 Certificate of patent or registration of utility model

Ref document number: 7721520

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150